Vivani Medical GAAP EPS of -$0.12
Seeking Alpha · 05/15 11:15
Vivani Medical Q1 EPS $(0.12) Down From $(0.11) YoY; Cash Balance Of $38.1M Sufficient To Fund Operations Into 2H Of 2024
Benzinga · 05/15 10:31
BRIEF-Vivani Medical Reports First Quarter Financial Results And Provides Business Update
Reuters · 05/15 10:24
Vivani Medical: Current report
Press release · 05/15 06:53
Vivani Medical: Quarterly report
Press release · 05/15 06:50
TScan, Vivani top healthcare gainers; Community Health, Jin Medical lead losers' pack
Seeking Alpha · 05/02 14:02
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 05/02 13:06
Over $2M Bet On Vivani Medical? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
Benzinga · 05/02 12:37
TUP, VANI and CNET are among pre-market gainers
Seeking Alpha · 05/02 12:19
BRIEF-Joachim Bolck Reports 11.03% Stake In Vivani Medical Inc - SEC Filing
Reuters · 04/25 21:36
Vivani stock pops on final $1M NIH grant for artificial vision device study
Seeking Alpha · 04/04 10:45
BRIEF-Vivani Medical Announces $1 Million NIH Grant Funding
Reuters · 04/04 10:26
National Institutes Of Health Approved Year 5 Funding For The Early Feasibility Clinical Study Of The Orion Visual Cortical Prosthesis Conducted By Vivani Medical's, Cortigent. This Represents The Final $1M Funding Of The Original $6.4M Five-Year Award
Benzinga · 04/04 10:04
Vivani Medical Receives Final $1 Million National Institutes of Health Grant Funding for Orion Clinical Study
Vivani Medical Receives Final $1 Million National Institutes of Health Grant Funding for Orion Clinical Study
MT Newswires · 04/04 08:11
Second Sight Medical, Now Part Of Vivani Medical, Has Received An Additional $1M Of NIH Funding For The Project "Early Feasibility Clinical Trial Of A Visual Cortical Prosthesis"
Benzinga · 04/03 17:35
Vivani Medical Reports Q4 And FY22 Financial Results And Provides Business Update; FY22 EPS $(0.36) Vs $(0.39) YoY; As Of December 31, 2022, Vivani Had Cash And Cash Equivalents Totaling $45.1M
Benzinga · 03/31 19:26
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 03/24 13:06
BRIEF-Vivani Medical Announces Public Filing Of Registration Statement For The Proposed IPO Of Cortigent Inc
Reuters · 03/21 11:30
Cortigent, developer of human vision restoration devices, files for $17M IPO
Seeking Alpha · 03/20 23:13
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 12/29/2022 21:31
Webull provides a variety of real-time VANI stock news. You can receive the latest news about Vivani Medical through multiple platforms. This information may help you make smarter investment decisions.
About VANI
Vivani Medical, Inc. is a preclinical-stage biopharmaceutical company. The Company develops miniaturized and subdermal implants utilizing its NanoPortal technology to enable the delivery of a range of medicines to treat chronic diseases. It uses this platform technology to develop and commercialize drug implant candidates for the treatment of chronic disease and medication non-adherence. NanoPortal implant technology's initial focus is on peptide therapeutics for the treatment of patients with metabolic diseases. It operates through two segments: Biopharm Division and Neuromodulation Division. Its pipeline product candidates include NPM-119, NPM-159, NPM-139 and OKV-119. Its lead product, NPM-119, is a GLP-1 receptor agonist under development to treat patients with type two diabetes. NPM-159 is in feasibility testing for the treatment of non-alcoholic steatohepatitis (NASH). It is also in the development of neurostimulation systems to help patients recover critical body functions.